These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35784333)

  • 1. Co-Inhibitory Molecules - Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events.
    Greisen SR; Aspari M; Deleuran B
    Front Immunol; 2022; 13():883733. PubMed ID: 35784333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.
    Greisen SR; Deleuran B
    Curr Rheumatol Rep; 2021 Mar; 23(4):22. PubMed ID: 33651184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist.
    Jamal S; Hudson M; Fifi-Mah A; Ye C
    J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity.
    Thanarajasingam U; Abdel-Wahab N
    Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H; Zhou J; Xu D; Zeng X
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.
    Calabrese LH; Caporali R; Blank CU; Kirk AD
    J Autoimmun; 2020 Dec; 115():102546. PubMed ID: 32980229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of immune checkpoint therapy in autoimmune diseases.
    Mohammadi P; Hesari M; Chalabi M; Salari F; Khademi F
    Int Immunopharmacol; 2022 Jun; 107():108647. PubMed ID: 35228033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
    van der Vlist M; Kuball J; Radstake TR; Meyaard L
    Nat Rev Rheumatol; 2016 Oct; 12(10):593-604. PubMed ID: 27539666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationships between cancer and autoimmune rheumatic diseases.
    Cappelli LC; Shah AA
    Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101472. PubMed ID: 32029389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell checkpoints in autoimmune rheumatic diseases.
    Rubin SJS; Bloom MS; Robinson WH
    Nat Rev Rheumatol; 2019 May; 15(5):303-315. PubMed ID: 30967621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events induced by immune checkpoint inhibitors.
    Perdigoto AL; Kluger H; Herold KC
    Curr Opin Immunol; 2021 Apr; 69():29-38. PubMed ID: 33640598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulatory and Inhibitory Co-signals in Autoimmunity.
    Okazaki T; Okazaki IM
    Adv Exp Med Biol; 2019; 1189():213-232. PubMed ID: 31758536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
    Bucktrout SL; Bluestone JA; Ramsdell F
    Genome Med; 2018 Oct; 10(1):79. PubMed ID: 30376867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
    Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
    Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.
    Schnell A; Bod L; Madi A; Kuchroo VK
    Cell Res; 2020 Apr; 30(4):285-299. PubMed ID: 31974523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint blockade therapy.
    Wieder T; Eigentler T; Brenner E; Röcken M
    J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.